OR WAIT null SECS
Croda has entered into an agreement with the US government to support the expansion of its lipid systems capability.
Croda has entered into a cooperative agreement with the United States government, in which the government will provide up to $75 million to expand the company’s US manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as messenger RNA (mRNA) vaccines.
Croda will also invest up to $58 million, bringing the total project investment to up to $133 million. The investment will be used to establish a new lipid facility as part of a new multi-purpose current good manufacturing practices (CGMP) site in Lamar, Pa. The new capacity is expected to be completed in 2025.
The new facility is part of a program to expand the US industrial base supporting critical vaccine and therapeutic manufacturing activities. The Lamar facility will ensure there is enough capacity available in the US to produce the necessary components for vaccine manufacture.
“We are grateful to the US government for its support of Croda. The delivery technology based on lipid systems offers significant potential for the safe and efficient delivery of next generation vaccines and therapeutic drugs,” said Daniele Piergentili, president of Croda Life Sciences, in a company press release. “As a result of this investment, Croda will be able to expand its capabilities to develop and manufacture ingredients in support of this important technology. This will help ensure that the US is well prepared for future health emergencies and equipped to offer advanced treatments for some of the most prevalent illnesses in the world today.”